KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $24.8 million.

  • NovoCure's Change in Accured Expenses rose 23319.91% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.7 million, marking a year-over-year increase of 9686.08%. This contributed to the annual value of $19.1 million for FY2024, which is 2849.55% up from last year.
  • Per NovoCure's latest filing, its Change in Accured Expenses stood at $24.8 million for Q3 2025, which was up 23319.91% from $5.9 million recorded in Q2 2025.
  • In the past 5 years, NovoCure's Change in Accured Expenses registered a high of $24.8 million during Q3 2025, and its lowest value of -$18.2 million during Q1 2024.
  • Over the past 5 years, NovoCure's median Change in Accured Expenses value was $6.3 million (recorded in 2023), while the average stood at $4.8 million.
  • Per our database at Business Quant, NovoCure's Change in Accured Expenses surged by 116469.14% in 2021 and then plummeted by 46393.75% in 2022.
  • Quarter analysis of 5 years shows NovoCure's Change in Accured Expenses stood at $17.2 million in 2021, then dropped by 5.85% to $16.2 million in 2022, then rose by 16.77% to $18.9 million in 2023, then grew by 7.9% to $20.4 million in 2024, then increased by 22.01% to $24.8 million in 2025.
  • Its Change in Accured Expenses stands at $24.8 million for Q3 2025, versus $5.9 million for Q2 2025 and -$16.4 million for Q1 2025.